OPNT Insider Trading Activity and SEC Form 4 Filings
OPNT insider trading summary
No open-market insider purchases or sales of Opiant Pharmaceuticals, Inc. (OPNT) have been reported on SEC Form 4 in the past 12 months.
Latest OPNT insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jan 27, 2023 | Roger Crystal | Chief Executive Officer | Sell | $28K (1,358 @ $20.26) |
| Jan 27, 2023 | David D O'Toole | Chief Financial Officer | Sell | $11K (541 @ $20.26) |
| Jan 27, 2023 | Mark Jason Heath Ellison | Chief Development Officer | Sell | $12K (610 @ $20.26) |
| Jan 27, 2023 | Phil Skolnick | Chief Scientific Officer | Sell | $10K (480 @ $20.26) |
| Jan 27, 2023 | Brian Gorman | Insider | Sell | $9K (444 @ $20.26) |
| Jan 9, 2023 | Mark Jason Heath Ellison | Chief Development Officer | Sell | $9K (469 @ $20.20) |
| Jan 9, 2023 | David D O'Toole | Chief Financial Officer | Sell | $8K (415 @ $20.20) |
| Jan 9, 2023 | Phil Skolnick | Chief Scientific Officer | Sell | $7K (369 @ $20.20) |
| Jan 9, 2023 | Roger Crystal | Chief Executive Officer | Sell | $24K (1,183 @ $20.20) |
| Jan 5, 2023 | Mark Jason Heath Ellison | Chief Development Officer | Sell | $36K (1,806 @ $20.20) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.